In oncology, a diagnostic result is more than a numerical value—it represents a snapshot of complex and evolving tumor biology. At Arni Medica, our approach to cancer diagnostics is grounded in a deep understanding of this biology, built through years of focused research into bioactive compounds and their interaction with cancer pathways.
Dr. Parvathaneni's research investigations into lignans - provided early and critical insights into cancer biology. These studies demonstrated dose-dependent inhibition of cancer cell lines and significant tumor burden reduction in in-vivo models. Beyond documenting outcomes, this research explored molecular mechanisms influencing tumor proliferation, apoptosis, and cellular metabolism.
This mechanistic engagement with cancer biology informs Arni Medica’s diagnostic philosophy. Effective cancer monitoring requires more than detecting a biomarker—it requires understanding its biological relevance, clinical behavior, and relationship to disease progression.
This research-driven perspective directly influences our tumor marker strategy:
Insights into cellular proliferation and apoptosis support the clinical utility of CYFRA 21-1 as a dynamic indicator of tumor cell turnover rather than a static marker.
Understanding metabolic and kinetic behavior informs the interpretation of PSA trends in prostate cancer monitoring.
Recognition of tumor heterogeneity reinforces the value of multi-marker panels (e.g., CEA, CA 19-9, CA 125) for comprehensive disease assessment.
Building on this foundation, Arni Medica offers a strategically curated oncology diagnostics portfolio across CLIA and FIA platforms, selected for clinical relevance and complementary diagnostic value:
Hepatic & GI Cancers: AFP, CEA, CA 19-9
Prostate Health: Total PSA, Free PSA
Gynecological Cancers: CA 125, HE4
Lung Cancers: CYFRA 21-1, NSE, ProGRP, SCC
Breast Cancer: CA 15-3
Broad-Spectrum Monitoring: Ferritin, β-hCG, CA 72-4
These markers are delivered on high-sensitivity platforms designed to detect subtle, clinically meaningful changes—supporting early detection, recurrence monitoring, and therapy assessment.
Arni Medica’s research background enables:
Contextual Interpretation: Understanding biomarker behavior within disease pathways
Optimized Panel Design: Clinically relevant marker combinations rather than isolated testing
Assay Performance Insight: Pharmacokinetic expertise (P3) guiding sensitivity, specificity, and dynamic range considerations
As cancer research continues to uncover new biomarkers and molecular signatures, Arni Medica remains committed to translating validated scientific knowledge into reliable diagnostic solutions. Our goal is to bridge rigorous cancer research with practical, scalable diagnostics that support clinicians and laboratories across diverse healthcare settings.
Interested in implementing a science-led oncology diagnostics strategy?
Contact our scientific team at research@arnimedica.com to discuss optimized tumor marker panels and platform solutions.
Research Publications:
P1: Investigation of anticancer potential of hypophyllanthin and phyllanthin against breast cancer by in-vitro and in-vivo methods https://doi.org/10.1016/S2222-1808(14)60417-5
P2: Cancer biomarkers and translational research perspectives https://doi.org/10.1016/j.semcancer.2017.10.010
P3: Pharmacokinetic study of phyllanthin and hypophyllanthin after oral administration https://www.phcogj.com/article/1551
